Pharmacological Treatment of Refractory Bipolar Disorder: What Does the Evidence Say?

Konstantinos N Fountoulakis*
3rd Department of Psychiatry, Aristotle University of Thessaloniki, Greece

Abstract

Bipolar disorder constitutes a therapeutic challenge. In spite of intense research on its treatment during the last decades, the data on the treatment of refractory bipolar patients are sparse. For acutely manic patients who are partial responders to lithium, valproate or carbamazepine, a good strategy would be to add haloperidol, risperidone, olanzapine, quetiapine or aripiprazole. Adding oxcarbazepine to lithium is also a choice. The treatment of refractory bipolar depressives remains terra incognita and also there is no compelling data for the maintenance treatment of refractory patients. Patients stabilized on combination treatment might do worse if shifted from combination. Conclusively there are only limited and sometimes confusing data on the treatment of refractory bipolar patients. Further focused research is necessary on this group of patients.

Introduction

The treatment of Bipolar Disorder (BD) is complex and full of caveats for the clinician [1-4]. The presence of residual affective symptoms is associated with a greater risk of relapse and poorer functional outcomes. In this frame, remission is a more desirable treatment target, however a significant proportion of patients are rather refractory to treatment and their outcome is at best suboptimal.

Several older studies (most of them open trials) have defined treatment refractoriness on the basis of an inadequate response to a therapeutic trial of lithium or an inability to tolerate lithium's side effects [5-10]. Some authors utilized only lithium non-response or intolerance [5,6], others included an alternate nonresponse/intolerance to carbamazepine [5,7] or valproate [10] while others required nonresponse to at least two or more mood-stabilizing medications including antipsychotics [6,10-15]. The current article attempts to perform a review of the treatment of refractory bipolar patients [16,17].

Definition of Refractoriness in Bipolar Disorder

Currently, the International Society on Bipolar Disorder (ISBD) definitions is the most comprehensive and updated. They utilize both a syndromal (on the basis of DSM criteria) and symptomatic (on the basis of rating scales) approach. These definitions recommend the use of incremental steps for symptom improvement (<25%; 25–49%; 50–74%; 75–100%) in order to define response. They propose multiple cut-off points for the definition of remission with the most stringent being <6 for HDRS-17 and MADRS and <5 for the YMRS in the cases of depression and mania respectively. These stringened criteria made possible the consideration of subsyndromal states which are very important in BD (7-14 in HDRS or MADRS and 8-14 in YMRS). 'Recovery' is defined as sustained remission after at least 8 weeks [18], which is similar to the approach of the AMA [19]. The ISBD definitions suggest that noncriterion symptoms that are commonly associated with BD (usually during the depressive phase) such as anxiety, panic attacks, irritability, hopelessness, avoidance, or cognitive dysfunction should not be included in the definitions [18]. It is interesting that the ISBD definitions do not include functioning in their criteria while other authors do include it [20].

A dilemma when defining response, remission and refractoriness in BD is whether the definitions will narrowly concern each phase and pole (e.g. refractory acute mania or refractory recurrent mania) or the disease as a whole. The first approach will be easier to operationalize, but the second is more clinically oriented and meaningful.

Another problem is that not all agents and therapeutic modalities traditionally used in the treatment of BD have proven efficacy against the specific facets of the disorder they are used against, and even more important, there is little 'class effect' in the treatment of BD.

The third problem concerns trial duration. It is necessary to wait for sufficient time for the agent to act. Taken the data altogether it seems that at least 10-12 weeks of duration should be the minimum of a therapeutic acute phase trial before the patient should be considered as non-responder. During the maintenance phase it is reasonable to consider response and refractoriness in the frame of 1 year (52 weeks) duration, remission should require at least 2-3 years and recovery 3-5, because of the episodic nature of the illness.

In table 1, a summary of practical criteria for response, remission and recovery, developed by the author [21] and based on the ISBD definitions [18] are shown.

Treatment Modalities with Proven Efficacy in BD

The author has already published several reviews on the evidence concerning the pharmacological treatment of bipolar disorder [1,3,4,16,17,21-41]. The current paper is based on these previous studies and the reader is encouraged to utilize them for details. The review of the data was updated through May 1st 2013. A list of agents with proven efficacy against the various facets of BD is shown in table 2.

Treatment of Refractory Cases

Refractory mania

Combination studies do not support the proposal that combination

*Corresponding author: Konstantinos N Fountoulakis MD, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, 6, Odysseos str (1st Parodos Ampelion str.), 55535 Pylaia Thessaloniki, Greece, Tel: +30-2310 435702; Fax: +30-2310-266570; E-mail: kfount@med.auth.gr

Received May 03, 2013; Accepted May 27, 2013; Published June 09, 2013


Copyright: © 2013 Fountoulakis KN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Treatment Resistant Mood Disorders were negative [62-64]. More recently one study used imipramine as adjunctive therapy on lithium in bipolar depression. Studies of adding oxcarbazepine to lithium are limited. Most studies are negative. Older add-on studies of refractory bipolar depression would be to add haloperidol, risperidone, olanzapine, quetiapine or aripiprazole. Adding oxcarbazepine to lithium is also a good strategy.

Three phase crossover and eventually combination treatment of lithium or a mood stabilizer increases the response rate [66-68]. Similar findings were reported for citalopram [69], paroxetine and amitriptyline [70]. The problem is that the above studies are not placebo-controlled, and unfortunately, a recent double-blind, placebo-controlled study, of adding an antidepressant on a mood stabilizer in 179 bipolar depressed patients was negative [71]. On the contrary another earlier study reported the usefulness of paroxetine as add on therapy [72]. A more recent study reported that adding lamotrigine to lithium was better than placebo in patients with bipolar depression under long term lithium treatment [73] and another recent 8 week trial on 52 incomplete responders utilizing adding carbamazepine or oxcarbazepine (600-1200 mg daily) during maintenance treatment (results are more relevant to the acute depressive phase) with lithium was positive [50]. Recently one add-on study with ziprasidone (NCT00483548) was negative.

Strictly speaking, there are no reliable data concerning the treatment of refractory bipolar depressives. Since only quetiapine and the OFC are the only treatment options with proven efficacy against this condition, RCTs with patients who fail under them are necessary. Until today, such studies do not exist and existing data cannot be considered to concern refractory patients.

Refractory Maintenance

There are only few RCTs utilizing refractory patients. In a three phase crossover and eventually combination treatment of lithium plus carbamazepine, the results suggested that there was no further improvement for patients although rapid cycling patients do better under combination than under monotherapy (28.0% responded to lithium; 19.0% responded to carbamazepine and 56.3% to their

<table>
<thead>
<tr>
<th>phase</th>
<th>Scale scores</th>
<th>Trial duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute mania</td>
<td>&lt;25%, 25–49%, 50–74%, 75–100% reduction in YMRS or MRS scores</td>
<td>8-10 weeks</td>
</tr>
<tr>
<td></td>
<td>No significant increase in MADRS or HDRS scores and MADRS and HDRS scores stay below 6</td>
<td></td>
</tr>
<tr>
<td>Acute Bipolar</td>
<td>&lt;25%, 25–49%, 50–74%, 75–100% reduction in MADRS or HDRS scores</td>
<td>10-12 weeks</td>
</tr>
<tr>
<td>depression</td>
<td>No significant increase in YMRS or MRS scores and YMRS and MRS scores stay below 5</td>
<td></td>
</tr>
<tr>
<td>Remission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute mania</td>
<td>YMRS and MRS scores stay below 5</td>
<td>1 year</td>
</tr>
<tr>
<td>Acute Bipolar</td>
<td>MADRS and HDRS scores stay below 6</td>
<td></td>
</tr>
<tr>
<td>depression</td>
<td>No significant increase in YMRS or MRS scores and YMRS and MRS scores stay below 5</td>
<td></td>
</tr>
<tr>
<td>maintenance</td>
<td>Very rare new episodes, and MADRS/HDRS scores &lt;6 and YMRS/MRS scores &lt;7 between episodes</td>
<td>2-3 years?</td>
</tr>
<tr>
<td>Acute mania</td>
<td>YMRS and MRS scores stay below 5</td>
<td>8 weeks</td>
</tr>
<tr>
<td>Acute Bipolar</td>
<td>MADRS and HDRS scores stay below 6</td>
<td>8 weeks</td>
</tr>
<tr>
<td>depression</td>
<td>No significant increase in YMRS or MRS scores and YMRS and MRS scores stay below 5</td>
<td></td>
</tr>
<tr>
<td>maintenance</td>
<td>No new mood episodes and MADRS/HDRS scores &lt;6 and YMRS/MRS scores &lt;7 between episodes</td>
<td>3-5 years?</td>
</tr>
<tr>
<td>Refractoriness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute mania</td>
<td>No significant reduction in YMRS or MRS scores, or significant increase in MADRS or HDRS scores or MADRS and HDRS scores exceed 6</td>
<td>8-10 weeks</td>
</tr>
<tr>
<td>Acute Bipolar</td>
<td>No significant reduction in YMRS or MRS scores, or significant increase in MADRS or HDRS scores or MADRS and HDRS scores exceed 5</td>
<td>10-12 weeks</td>
</tr>
<tr>
<td>depression</td>
<td>No change in the frequency of episodes, or MADRS/HDRS scores &gt;6 or YMRS/MRS scores &gt;7 between episodes</td>
<td>1 year</td>
</tr>
</tbody>
</table>

Table 1: Practical definitions of response, remission, recovery and refractoriness, based mainly on the ISBD criteria.
Clozapine is superior to treatment as usual in the prevention of mania in refractory patients \[75\]. One study reports that adding lamotrigine to lithium was better than placebo in patients with bipolar depression under long term lithium treatment \[73\]. A 40 week placebo controlled extension study of the safety and efficacy of Asenapine when added to lithium or valproate was inconclusive because of high drop out rate \[56\] and a 40 week extension study of asenapine vs. olanzapine (Ares 7501007) is expected to be announced.

<table>
<thead>
<tr>
<th>Table 2: Therapy data</th>
</tr>
</thead>
<tbody>
<tr>
<td>++++: strong positive evidence on the basis of placebo-controlled RCTs</td>
</tr>
<tr>
<td>++*: unpublished data; suggested with reservation</td>
</tr>
<tr>
<td>++: evidence on the basis of RCTs but without placebo arm or with small study sample</td>
</tr>
<tr>
<td>+: positive evidence on the basis of open studies</td>
</tr>
<tr>
<td>neg: strong negative data on the basis of RCTs</td>
</tr>
<tr>
<td>E: equivocal data</td>
</tr>
<tr>
<td>m: manic/mixed episode</td>
</tr>
<tr>
<td>d: depressive episode</td>
</tr>
<tr>
<td>m/d: either manic/mixed or depressive episode</td>
</tr>
<tr>
<td>m*: with proven efficacy in the prevention of mania only in refractory patients</td>
</tr>
</tbody>
</table>
Psychological treatments

Adding a psychological treatment to pharmacotherapy, especially in refractory patients, is a standard in psychiatry, although hard data are limited. Data are positive for cognitive therapy [76,77], intensive psychotherapy with family-focused therapy, interpersonal and social rhythm therapy, [77] and psychoeducation [78-84].

The gradings of data concerning each treatment modality for the different phases of BD are shown in Table 2.

Other agents and therapeutic modalities

A number of medications outside the usual groups and classes might be useful especially in the treatment of complex and resistant cases. Benzodiazepines can be used as adjunctive medication. They are not considered effective against the core symptoms of bipolar illness; however they could be useful because of their anti-anxiety and sedative properties. Their major problem is addiction and tolerance as well as many interactions with other medications.

Recent placebo-controlled RCTs support the efficacy of the purinergic agents’ allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania [85], of celexcoxib as an adjunct in the treatment of mixed episodes with a rapid action [86] and of folic acid as an adjunct to valproate [87]. Dopaminergic agents and especially pramipexole could be useful in the treatment of bipolar depression either as monotherapy or as add on therapy [88,89]. Inositol could also be used as an augmenting agent in refractory depressive patients [90] and N-acetyl cysteine for maintenance [91]. Recently a placebo-controlled study of adjunctive modafinil has been shown to improve the outcome of bipolar depression without switching to mania or hypomania [92], however subclinical switches could be present [93]. Data are also positive for ketamine [94,95].

Older clinical observations and some more recent clinical trials support the efficacy of electroconvulsive therapy (ECT) in acute mania, and in treatment resistant bipolar depression [96-102], although there are no definite data. Transcranial magnetic stimulation (rTMS) of the brain at 20 Hz over the right but not left frontal cortex or 1 Hz bi-frontally is reported to be effective. However data are still insufficient and no conclusions can be drawn [103-106].

Sleep deprivation and other noninvasive circadian-related interventions could be useful add-on treatment in order to accelerate and sustain antidepressant response [107].

However augmentation strategies have not been tested adequately and most of them cannot be considered to have proven efficacy beyond doubt. Augmentation strategies are summarized in table 3.

Discussion

The current study reviews the issue of treatment of refractory bipolar patients. It is obvious that the data are limited and might provide with insight only in the case of acute mania. Ironically, acute mania is the least problematic phase in comparison to acute bipolar depression or the maintenance phase.

For refractory manic patients, the combination of Li or valproate with aripiprazole, olanzapine, risperidone and maybe quetiapine or asenapine is recommended. Some reports suggest the use of ECT or higher dosages of neuroleptics, but the data are insufficient. Unfortunately there are even fewer data to support a valid strategy to cope with refractory bipolar depressive cases and with maintenance treatment.

Thus the paucity of data leaves the clinician with the heavy burden to decide on the basis of clinical experience and wisdom. In this frame, existing treatment guidelines cannot be considered to rely on hard data after their first step recommendations. Future research is essential and necessary to test possible treatment approaches for refractory patients of all kinds.

This research should utilize operationalized definitions on the basis of treatments with proven efficacy against the respected condition. Add-on studies or combination studies might give some kind of information; however the interpretation is complex and so far failed to provide reliable ground for decision-making. The ‘superiority design’ concept of these studies with the use of non-refractory patients might reflect a specific logic in the approach of the problem but so far has been proven to be inadequate.

Conflict of interest

Dr Fountoulakis is/was member of the International Consultation Board of Wyeth for desvenlafaxine, BMS for aripiprazole in bipolar disorder and Servier for agomelatine and has received honoraria for lectures from AstraZeneca, Janssen-Cilag, Eli-Lilly and research grants from AstraZeneca and Pfizer Foundation.

References


Table 3: List of agents studied for augmentation strategies.


Submit your next manuscript and get advantages of OMICS Group submissions

**Unique features:**
- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

**Special features:**
- 250 Open Access Journals
- 30,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc.
- Sharing, Option Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific credits
- Better discount for your subsequent articles

Submit your manuscript at: [www.omicsgroup.org/journals/submission/](http://www.omicsgroup.org/journals/submission/)

This article was originally published in a special issue, Treatment Resistant Mood Disorders handled by Editor(s), Dr. Jan Fawcett, University of New Mexico School of Medicine, USA
